These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16239760)

  • 1. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.
    Chou KL; Messing S; Oakes D; Feldman PD; Breier A; Friedman JH
    Clin Neuropharmacol; 2005; 28(5):215-9. PubMed ID: 16239760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis.
    Kulick CV; Montgomery KM; Nirenberg MJ
    Parkinsonism Relat Disord; 2018 Sep; 54():40-45. PubMed ID: 29653909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders.
    McKetin R; Baker AL; Dawe S; Voce A; Lubman DI
    Psychiatry Res; 2017 May; 251():349-354. PubMed ID: 28282630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scales to assess psychosis in Parkinson's disease: Critique and recommendations.
    Fernandez HH; Aarsland D; Fénelon G; Friedman JH; Marsh L; Tröster AI; Poewe W; Rascol O; Sampaio C; Stebbins GT; Goetz CG
    Mov Disord; 2008 Mar; 23(4):484-500. PubMed ID: 18175343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Threatening auditory hallucinations and Cotard syndrome in Parkinson disease.
    Factor SA; Molho ES
    Clin Neuropharmacol; 2004; 27(5):205-7. PubMed ID: 15602098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia.
    Barrett MJ; Smolkin ME; Flanigan JL; Shah BB; Harrison MB; Sperling SA
    Parkinsonism Relat Disord; 2017 Oct; 43():56-60. PubMed ID: 28735797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cocaine-induced psychosis.
    Brady KT; Lydiard RB; Malcolm R; Ballenger JC
    J Clin Psychiatry; 1991 Dec; 52(12):509-12. PubMed ID: 1752853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study.
    Fernandez HH; Okun MS; Rodriguez RL; Malaty IA; Romrell J; Sun A; Wu SS; Pillarisetty S; Nyathappa A; Eisenschenk S
    Int J Neurosci; 2009; 119(12):2196-205. PubMed ID: 19916848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.
    Cummings JL; Street J; Masterman D; Clark WS
    Dement Geriatr Cogn Disord; 2002; 13(2):67-73. PubMed ID: 11844887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
    Juncos JL; Roberts VJ; Evatt ML; Jewart RD; Wood CD; Potter LS; Jou HC; Yeung PP
    Mov Disord; 2004 Jan; 19(1):29-35. PubMed ID: 14743357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
    Clark WS; Street JS; Feldman PD; Breier A
    J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Psychoses in patients with Parkinson's disease; their frequency, phenomenology, and clinical correlates].
    Kashihara K; Ohno M; Katsu Y
    Rinsho Shinkeigaku; 2005 Jan; 45(1):1-5. PubMed ID: 15714992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients.
    Zarrabi H; Khalkhali M; Hamidi A; Ahmadi R; Zavarmousavi M
    BMC Psychiatry; 2016 Feb; 16():44. PubMed ID: 26911516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hallucinations and psychosis in Parkinson's disease.
    Eng ML; Welty TE
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):316-30. PubMed ID: 20869621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.
    De Deyn PP; Carrasco MM; Deberdt W; Jeandel C; Hay DP; Feldman PD; Young CA; Lehman DL; Breier A
    Int J Geriatr Psychiatry; 2004 Feb; 19(2):115-26. PubMed ID: 14758577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms.
    Lee AH; Weintraub D
    Mov Disord; 2012 Jun; 27(7):858-63. PubMed ID: 22674352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.
    Aarsland D; Larsen JP; Cummins JL; Laake K
    Arch Neurol; 1999 May; 56(5):595-601. PubMed ID: 10328255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delusions and hallucinations of cocaine abusers and paranoid schizophrenics: a comparative study.
    Mitchell J; Vierkant AD
    J Psychol; 1991 May; 125(3):301-10. PubMed ID: 1880755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease.
    Udow SJ; Freitas ME; Fox SH; Lang AE
    CMAJ; 2018 Jan; 190(2):E50-E52. PubMed ID: 29335263
    [No Abstract]   [Full Text] [Related]  

  • 20. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase.
    Pagonabarraga J; Martinez-Horta S; Fernández de Bobadilla R; Pérez J; Ribosa-Nogué R; Marín J; Pascual-Sedano B; García C; Gironell A; Kulisevsky J
    Mov Disord; 2016 Jan; 31(1):45-52. PubMed ID: 26408291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.